Share on StockTwits

Clinigen Group PLC (LON:CLIN)‘s stock had its “buy” rating reissued by N+1 Singer in a research note issued on Wednesday. They currently have a GBX 439 ($7.34) target price on the stock. N+1 Singer’s target price would suggest a potential upside of 9.02% from the stock’s previous close.

A number of other firms have also recently commented on CLIN. Analysts at Investec reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Thursday, July 24th. Separately, analysts at Numis Securities Ltd reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Thursday, July 24th. They now have a GBX 650 ($10.87) price target on the stock. Finally, analysts at Oriel Securities Ltd reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Thursday, July 24th. They now have a GBX 650 ($10.87) price target on the stock. Five analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of GBX 592.20 ($9.90).

Shares of Clinigen Group PLC (LON:CLIN) opened at 429.875 on Wednesday. Clinigen Group PLC has a 52-week low of GBX 354.92 and a 52-week high of GBX 690.00. The stock’s 50-day moving average is GBX 378.4 and its 200-day moving average is GBX 469.7.

Clinigen Group plc (LON:CLIN) is a specialty pharmaceuticals and services business company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.